Xarelto Acute Coronary Syndromes Claim Faces Data Quality Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask its cardio-renal advisory committee whether missing data in J&J/Bayer’s ATLAS study affects the interpretability of rivaroxaban’s demonstrated efficacy in acute coronary syndromes. The panel also will be asked whether the agency should pre-specify clinical trial standards for data quality to reduce the problems associated with missing data in CV outcomes studies.
You may also be interested in...
FDA Questions Evidence For Janssen’s Xarelto In Acute Coronary Syndrome
Although FDA suggested the sponsor consider a limited duration of use for rivaroxaban in the ACS setting, advisory committee briefing documents reflect doubts about the strength of analyses supporting such a claim.
FDA Panel To Take Second Look After J&J Plugged Holes In Xarelto ATLAS Data
Broader issue of missing data in clinical trials could see further discussion as FDA’s Cardiovascular and Renal Advisory Committee will relook at Xarelto’s acute coronary syndrome indication Jan. 16, now that J&J has tried to address the missing data that befuddled the committee on the first go-round.
Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter
FDA could have concerns about the reported data from the ARISTOTLE trial, either from the bleeding comparisons or the dosing in the warfarin control arm. Missing data is another possible issue, as in the recent “complete response” letter for J&J/Bayer’s Xarelto.